Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax (NVAX) is exploring new partnerships and advancing its vaccine pipeline. Sanofi is testing a COVID-flu combo vaccine, and Novavax's Nuvaxovid is in U.S. retailers. The company aims for profitability by 2029 and has $6.8B in global COVID-19 vaccine sales last year, with U.S. demand down slightly. Novavax is also developing an oncology vaccine and a C. difficile vaccine, with trials potentially starting in 2027.





